ストックスクリーナーアプリを入手
0.846
4.53%
-0.0401
アフターアワーズ：
.89
0.044
+5.20%
前日終値:
$0.8861
開ける：
$0.8856
24時間の取引高:
177.66K
Relative Volume:
0.87
時価総額：
$40.30M
収益：
$8.38M
当期純損益:
$-27.19M
株価収益率:
-0.7761
EPS:
-1.09
ネットキャッシュフロー:
$-13.59M
1週間 パフォーマンス:
-13.83%
1か月 パフォーマンス:
-15.26%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.8007
$0.8859
1週間の範囲:
$0.8007
$1.14
52週間の値動き範囲:
$0.8007
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
IRD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
0.846 | 40.30M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-13 | 再開されました | H.C. Wainwright | Buy |
Opus Genetics Inc (IRD) 最新ニュース
Rexahn Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress - The Manila Times
Opus Genetics' Future at Stake: Ex-CEO Challenges $21.5M-Backed Gene Therapy Transformation - Stock Titan
Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts - Yahoo Finance
Opus Genetics Terminates Purchase Agreement with Lincoln Park - TipRanks
Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Opus Genetics to Participate in Upcoming Investor Conference in April - GlobeNewswire
Exclusive Ophthalmology Gene Therapy Updates: Opus Genetics CEO Takes Center Stage at RBC Conference - Stock Titan
Opus Genetics (NASDAQ:IRD) Receives Buy Rating from HC Wainwright - Defense World
Opus Genetics (NASDAQ:IRD) Price Target Cut to $8.00 by Analysts at Jones Trading - Defense World
Opus Genetics price target lowered to $8 from $9 at JonesResearch - TipRanks
H.C. Wainwright maintains $8 target on Opus Genetics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $8 target on Opus Genetics stock - Investing.com
Opus Genetics Announces Full Year 2024 Financial Results, Provides Corporate Update - VisionMonday.com
Opus Genetics earnings missed by $1.22, revenue fell short of estimates - Investing.com Canada
Opus Leans Lower on Year-End Figures - Baystreet.ca
Opus Genetics Announces Financial Results for Full Year 2024 - TradingView
Opus Genetics Transformation: $51.8M Cash Position Powers 4 Clinical Readouts in 2025 - Stock Titan
Ousted founder of drug development company tries to take back the reins - Crain's Detroit Business
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
Pleasing Signs As A Number Of Insiders Buy Opus Genetics Stock - simplywall.st
Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance
Opus Genetics closes $20M offering, issues private placement - Investing.com India
Opus Genetics closes $20M offering, issues private placement By Investing.com - Investing.com South Africa
Opus Genetics founder Mina Sooch files preliminary proxy materials for co board election - MarketScreener
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics - The Manila Times
Opus Genetics Prices Public Offering At $0.95/Share, Raising Over $20M - Nasdaq
Opus Genetics announces $21.5 million capital raise - Investing.com
Opus Genetics Prices Public Offering, Private Placement -March 21, 2025 at 09:33 am EDT - MarketScreener
Opus Genetics Announces Presentation on Phentolamine - GlobeNewswire
Opus Genetics announces $21.5 million capital raise By Investing.com - Investing.com Australia
1 Wall Street Analyst Thinks Tesla Will Hit $425. Is it a Buy Around $235? - The Globe and Mail
Opus Genetics, Inc. Announces $20 Million Public Offering and $1.5 Million Private Placement to Fund Clinical Development Initiatives - Nasdaq
Opus Genetics Announces Pricing of Public Offering and - GlobeNewswire
Opus Genetics Secures $21.5M Backing: Perceptive Advisors Leads Gene Therapy Push - Stock Titan
Opus Genetics reports $56.8 million loss for 2024 By Investing.com - Investing.com South Africa
Opus Genetics reports $56.8 million loss for 2024 - Investing.com
Form 424B5 Opus Genetics, Inc. - StreetInsider
Opus Genetics enhances shareholder rights, sues for patent infringement By Investing.com - Investing.com South Africa
Opus Genetics enhances shareholder rights, sues for patent infringement - Investing.com India
Opus Genetics grants stock options to new employees - Investing.com
Opus Genetics Approves Equity Awards for New Employees Under 2021 Inducement Plan - Nasdaq
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Examining the Potential Price Growth of TREX Co., Inc (TREX) - Knox Daily
Opus Genetics Strengthens Team with Strategic Stock Options Package for Key New Hires - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lumen21 Files Trademark Suit Over Rival's 2020 'Lumen' Rebrand - Bloomberg Law
US Space Force Can Proceed With $2.5 Billion Weapons Procurement - Bloomberg Law
Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug - Bloomberg Law
Disabled Applicant's Open-Book Exam Request Was Lawfully Denied - Bloomberg Law
1 Stock Under $50 with Exciting Potential and 2 to Ignore - The Globe and Mail
Opus Genetics Inc (IRD) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
大文字化:
|
ボリューム (24 時間):